- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
In 2006 researchers established that dogs could detect cancer by sniffing the exhaled breath of cancer patients. Now, using nanoscale arrays of detectors, two groups of investigators have shown that a compact mechanical device also can sniff out lung cancer in humans.
Hossam Haick, Ph.D., and his colleagues at the Israel Institute of Technology in Haifa, used a network of 10 sets of chemically modified carbon nanotubes to create a multicomponent sensor capable of discriminating between a healthy breath and one characteristic of lung cancer patients. This work appears in the journal Nano News. Meanwhile, Silvano Dragonieri, M.D., University of Bari, Italy, and his colleagues used a commercial nanoarray-based electronic "nose" to discriminate between the breath of patients with non-small cell lung cancer and chronic obstructive pulmonary disease (COPD). These results appear in the journal Lung Cancer.
The key development in Dr. Haick's team's work demonstrated that the electrical resistance of carbon nanotubes coated with nonpolymeric organic layers changes substantially when nonpolar organic molecules, such as those present in a breath, pass over the nanotubes. Uncoated nanotubes do not respond strongly to the type of nonpolar molecules found in the human breath.
Using 10 different organic coatings, the investigators created field-effect transistors comprising random networks of each of the different coated nanotubes, and the resulting array produces a characteristic change in electrical output when exposed to volatile nonpolar organic substances. A computational technique known as principal component analysis can decipher the complex signal change produced when mixtures of nonpolar organic molecules pass over the sensor network. When plotted in two dimensions, the data from a simulated set of "healthy" and "lung cancer" patients form two clear clusters that readily distinguish the two sets of patients. The investigators also showed that their device could identify healthy rats from those with chronic kidney failure.
Rather than designing their own device, Dr. Dragonieri's group used a Cyranose 320 built by Smiths Detection based in Pasadena, California. This hand-held electronic nose, which is used widely throughout the chemical and food processing industries, employs a nanocomposite sensor array to rapidly detect volatile organic compounds in the air.
In this study, Dr. Dragonieri's team collected breath samples from 10 patients with NSCLC, 10 with COPD, and 10 healthy controls. After drying the samples, the investigators analyzed them using the Cyranose 320 and its onboard statistical software. Smellprints, analogous to fingerprints, from the three groups of patients were clearly distinguishable, with no ambiguity among the three groups. The investigators note that these results warrant conducting a large-scale, prospective clinical trial to determine whether this system could be useful in real clinical settings, including physician offices.
About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda, MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016